

# Pharmacy Analytics Report

## **Passport Health Plan**

Reporting Period: October 2018 to December 2018  
Comparison Period: July 2018 to September 2018

*Report Filters: None*

## Table of Contents

### Pharmacy Analytics Report

Reporting Period: October  
2018 to December 2018

Tab	Description	Content Highlights
Table of Contents	Your current location. This page describes subsequent sections and high-level usage. For details on how to run the report and metric calculations, please visit the report User Guide for more information.	<a href="#">Pharmacy Dashboard User Guide (Confluence)</a>
KPI Dashboard	Contains traditional high-level pharmacy key performance indicators. This section serves as an overview for pharmacy spending, utilization, and trends.	<ul style="list-style-type: none"> <li>• PMPM</li> <li>• Utilization</li> <li>• Trend drivers</li> </ul>
Trend Drivers	Investigates the contributions of new products entering the market and price inflation for current drugs to the overall pharmacy cost trend.	<ul style="list-style-type: none"> <li>• Drug growth</li> <li>• New drugs</li> </ul>
Cost Savings	This section dives into potential savings as brand name medications are substituted by generic formulations (if available).	<ul style="list-style-type: none"> <li>• Generic prescribing rates</li> <li>• Substitution opportunities</li> <li>• Low value drugs</li> </ul>
Medication Adherence	Medication adherence is measured by Percent (or Proportion) of Days Covered (PDC) in this section. The rates are displayed by condition, drug class and providers.	<ul style="list-style-type: none"> <li>• Overall adherence (PDC rates)</li> <li>• PDCs for high impact classes, top drug subclasses, and high volume providers</li> </ul>
Fraud, Waste, & Abuse (FWA)	Contains utilization trends for controlled substances and specific opioids as well as pharmacy- and member-level FWA flags (created by Evolent Pharmacy Team).	<ul style="list-style-type: none"> <li>• Potential for opioid abuse</li> <li>• Additional potential for FWA</li> </ul>
Patient Safety	This section shows frequently prescribed drugs for certain conditions and diagnoses, and potential drug interactions for members taking two or more medications.	<ul style="list-style-type: none"> <li>• Drug interactions</li> <li>• Drug to diagnosis relationships</li> </ul>
Specialty Drugs	This section covers overall trend for high-cost specialty drugs and provides details on specific drugs and providers.	<ul style="list-style-type: none"> <li>• Specialty drug spend and utilization</li> <li>• Provider prescribing rates</li> </ul>
Supply Chain	This page compares cost in two parts: first looks at medical claims to see unit cost differences by site of care; second utilizes pharmacy claims to investigate potential savings opportunities in maintenance drugs filled by different distribution channels.	<ul style="list-style-type: none"> <li>• Site of care cost differences</li> <li>• Maintenance drugs</li> </ul>
Appendix	Additional information	<ul style="list-style-type: none"> <li>• FWA flags definitions</li> </ul>

## Key Performance Indicators


Pharmacy Analytics Report

Reporting Period: October  
2018 to December 2018


This section contains high level key performance indicators for this population and comparisons to prior period's performance. The overall PMPM change can be broken down into three components: utilization (change in total prescriptions), inflation (change in cost) and drug mix (generic, brand, multisource).

Category	Metric	Value	Performance Indicator <sup>1</sup>
PMPM	Premium PMPM	\$0.00	●
	Paid PMPM	\$66.04	▲
	Member Responsibility PMPM	\$0.20	●
	Ingredient Cost PMPM	\$64.35	▲
Utilization	% of Members with ≥ 1 Rx Claim	23.1%	▲
	Scripts per 1,000	10,746.7	▲
	% Brand	6.3%	▲
	% Generic	85.2%	●
	% Multisource	7.3%	●
Paid per Script	Overall Paid per Script	\$73.7	●
	Brand	\$0.6	●
	Generic	\$0.3	▲
	Multisource	\$0.1	▼
Adherence	Proportion of Days Covered (PDC)	53.6%	▲

1. Based on current to prior reporting period % change - change within ± 2% indicated by ●.




The largest group (16%) in the reporting period is members taking 2-5 medications. The table below shows the top 15 drug groups with the highest change in utilization per thousand.



### Top 15 Drug Groups by Absolute Utilization per 1,000 Change

Drug Group (GPI 2)	Paid PMPM	Utilization per 1,000	% Change	Paid per Script	Cost per Unit
PASSIVE IMMUNIZING AND TREATMENT AGENTS	\$0.73	3.4	1415.1%	\$2,560.2	\$92.5
PHARMACEUTICAL ADJUVANTS	\$0.02	6.2	453.3%	\$45.1	\$4.0
VACCINES	\$0.42	88.4	147.0%	\$56.5	\$25.1
COUGH/COLD/ALLERGY	\$0.24	189.8	90.3%	\$15.4	\$1.6
MEDICAL DEVICES AND SUPPLIES	\$0.07	39.8	-52.3%	\$20.0	\$0.7
MACROLIDES	\$0.15	115.4	50.7%	\$15.3	\$2.8
ANTIVIRALS	\$7.95	83.1	43.2%	\$1,148.0	\$62.9
PENICILLINS	\$0.22	304.7	38.7%	\$8.6	\$0.9
DIAGNOSTIC PRODUCTS	\$0.65	60.9	-24.6%	\$127.2	\$4.6
CORTICOSTEROIDS	\$0.25	178.7	21.0%	\$16.9	\$2.2
Other	\$0.07	30.2	-21.0%	\$26.9	\$1.7
OTIC AGENTS	\$0.27	20.6	-20.9%	\$155.9	\$13.2
VASOPRESSORS	\$0.26	10.3	-20.5%	\$298.3	\$24.1
CEPHALOSPORINS	\$0.29	121.8	19.1%	\$28.4	\$3.0
ANALGESICS - NONNARCOTIC	\$0.08	164.2	16.3%	\$5.5	\$0.3


Overall ingredient cost per unit is increasing from prior period. This trend is a crucial contributor to the increase of overall PMPM in current period.



### Top 15 Drug Groups by Absolute Cost per Unit Change

Drug Group (GPI 2)	Paid PMPM	Utilization per 1,000	Paid per Script	Cost per Unit	% Change
PHARMACEUTICAL ADJUVANTS	\$0.02	6.2	\$45.1	\$4.0	171.5%
MULTIVITAMINS	\$0.44	62.1	\$85.6	\$2.9	-59.5%
MEDICAL DEVICES AND SUPPLIES	\$0.07	39.8	\$20.0	\$0.7	-46.9%
ANTIARRHEAL/PROBIOTIC AGENTS	\$0.02	11.7	\$17.3	\$1.0	40.6%
ANTIFUNGALS	\$0.11	67.2	\$20.3	\$3.6	34.7%
VASOPRESSORS	\$0.26	10.3	\$298.3	\$24.1	-26.6%
ANTHELMINTICS	\$0.08	2.4	\$401.9	\$48.9	-26.1%
PASSIVE IMMUNIZING AND TREATMENT AGENTS	\$0.73	3.4	\$2,560.2	\$92.5	-25.8%
GOUT AGENTS	\$0.07	21.8	\$36.9	\$1.3	-23.1%
MIGRAINE PRODUCTS	\$0.18	43.7	\$49.2	\$2.7	22.2%
HEMATOLOGICAL AGENTS - MISC.	\$0.35	37.2	\$111.9	\$3.1	-22.1%
VACCINES	\$0.42	88.4	\$56.5	\$25.1	-21.8%
COUGH/COLD/ALLERGY	\$0.24	189.8	\$15.4	\$1.6	21.6%
CEPHALOSPORINS	\$0.29	121.8	\$28.4	\$3.0	20.8%
PROGESTINS	\$0.27	13.3	\$238.9	\$9.8	-20.1%

The chart and table below summarize overall drug mix trend and changes in generic versus brand prescriptions. The Cost Savings section examines specific medications and prescribers where generic substitution opportunities exist.



### Drug Mix Change


Drug Type	Traditional	Specialty	Total
Brand	↑ 1.2%	↑ 3.1%	↑ 2.0%
Generic	↑ 12.3%	↑ 11.8%	↑ 12.3%
Total	↑ 4.3%	↑ 3.4%	↑ 4.0%

**Trend Drivers**  
Pharmacy Analytics Report

Reporting Period: October 2018  
to December 2018

The rising cost of prescription drugs are mainly due to existing drug price inflation and the entry of new products. This section of the dashboard investigates both, starting with the top 15 drug subclasses and top 25 individual medications with the highest period-over-period absolute PMPM change. The first graph displays the top 15 drug subclasses by their representative letter; they are divided into 4 quadrants:

1. Highest Priority: high cost and high growth rate
2. High Priority: low cost but high growth rate
3. Low Priority: high cost but low growth rate
4. Lowest Priority: low cost and low growth rate



Drug Subclass (GPI 6)	GPI 6 Growth Detail by Absolute PMPM Change <sup>1</sup>							
	Absolute PMPM Change	Paid PMPM		Scripts per 1,000		Paid per Script		
		Current	% Change	Current	% Change	Current	% Change	
A: B-COMPLEX W/ C & FOLIC ACID	\$0.81	\$0.35	-69.7%	2.3	-70.8%	\$1,817.3	3.8%	
B: OPIOID PARTIAL AGONISTS	\$0.38	\$3.02	14.2%	401.9	5.2%	\$90.1	8.6%	
C: ADRENERGIC COMBINATIONS	\$0.31	\$3.45	10.0%	126.6	9.2%	\$326.6	0.7%	
D: NEURAMINIDASE INHIBITORS	\$0.23	\$0.24	1798.3%	24.9	1395.3%	\$116.3	26.9%	
E: DIAGNOSTIC TESTS	\$0.23	\$0.65	-26.0%	60.8	-24.6%	\$127.3	-1.9%	
F: VIRAL VACCINES	\$0.19	\$0.36	117.1%	83.1	145.8%	\$51.5	-11.7%	
G: HEPATITIS C AGENT - COMBINATIONS	\$0.18	\$4.75	-3.7%	4.0	-6.4%	\$14,340.1	2.9%	
H: ANTINEOPLASTIC - TYROSINE KINASE INHIBITORS	\$0.15	\$0.85	21.2%	0.9	19.2%	\$11,252.4	1.7%	
I: QUINOLINONE DERIVATIVES	\$0.14	\$1.18	13.5%	49.8	5.8%	\$285.4	7.2%	
J: ANTICONSULSANTS - BENZODIAZEPINES	\$0.14	\$0.22	-38.0%	49.5	-1.8%	\$54.2	-36.9%	
K: INCRETIN MIMETIC AGENTS (GLP-1 RECEPTOR AGONISTS)	\$0.14	\$1.26	12.2%	20.8	11.9%	\$729.6	0.2%	
L: STEROID INHALANTS	\$0.13	\$0.76	21.5%	41.6	18.9%	\$219.5	2.2%	
M: ANAPHYLAXIS THERAPY AGENTS	\$0.13	\$0.20	-38.9%	8.2	-26.0%	\$296.2	-17.5%	
N: BETA ADRENERGICS	\$0.13	\$1.32	10.8%	303.3	15.1%	\$52.3	-3.7%	
O: OPIOID ANTAGONISTS	\$0.12	\$0.66	22.4%	12.2	15.8%	\$650.3	5.8%	

1. Drugs highlighted in red are not displayed in accompanying growth chart due to out-of-range current paid PMPM or PMPM growth %.

**Top 25 Drug Detail by Absolute PMPM Change**  
(minimum \$0.05 PMPM in current reporting period)

Drug	Drug Subclass (GPI 6)	Generic Indicator	Maintenance Indicator	Total Paid	Paid PMPM		Scripts per 1,000		Paid per Script	
					Current	% Change	Current	% Change	Current	% Change
OSELTAMIVIR PHOSPHATE	NEURAMINIDASE INHIBITORS	Y		\$228,976	\$0.24	1798.3%	24.9	1395.3%	\$116.3	26.9%
EMFLAZA	GLUCOCORTICOSTEROIDS		Y	\$49,785	\$0.05	812.3%	0.1	708.0%	\$6,223.2	12.9%
TREMFYA	ANTIPSORIATICS - SYSTEMIC	Y		\$61,561	\$0.06	500.0%	0.1	405.0%	\$12,312.3	18.8%
HUMIRA(CF) PEN	ANTI-TNF-ALPHA - MONOCLONAL ANTIBODIES		Y	\$142,223	\$0.15	484.8%	0.3	480.8%	\$6,183.6	0.7%
EPCLUSA	HEPATITIS C AGENT - COMBINATIONS			\$555,224	\$0.59	458.1%	0.3	480.8%	\$24,140.2	-3.9%
TAGRISSO	ANTINEOPLASTIC - TYROSINE KINASE INHIBITORS			\$58,944	\$0.06	304.0%	0.1	304.0%	\$14,736.1	0.0%
ADEMPAS	PULM HYPERTEN-SOLUBLE GUANYLATE CYCLASE STIMULATOR (SGC)		Y	\$68,863	\$0.07	257.4%	0.1	253.5%	\$9,837.5	1.1%
PROMACTA	THROMBOPOIETIN (TPO) RECEPTOR AGONISTS		Y	\$122,857	\$0.13	158.7%	0.2	64.1%	\$9,450.5	57.6%
VOTRIENT	ANTINEOPLASTIC - TYROSINE KINASE INHIBITORS		Y	\$73,256	\$0.08	152.5%	0.1	51.5%	\$12,209.3	66.6%
ORENCIA CLICKJECT	SELECTIVE COSTIMULATION MODULATORS		Y	\$49,981	\$0.05	142.4%	0.2	142.4%	\$4,165.1	0.0%
ACTEMRA	INTERLEUKIN-6 RECEPTOR INHIBITORS		Y	\$58,171	\$0.06	141.7%	0.2	145.3%	\$3,421.8	-1.5%
OZEMPIC	INCRETIN MIMETIC AGENTS (GLP-1 RECEPTOR AGONISTS)		Y	\$53,661	\$0.06	138.0%	0.9	137.8%	\$735.1	0.1%
BROMPHENIRAMINE-PSEUDOEPHED-DM	NON-NARC ANTI-TUSSIVE-DECONGESTANT-ANTIHISTAMINE	Y		\$144,096	\$0.15	135.7%	78.1	121.0%	\$23.3	6.7%
ORENCIA	SELECTIVE COSTIMULATION MODULATORS		Y	\$74,989	\$0.08	127.3%	0.2	127.3%	\$4,166.0	0.0%
HAVRIX	VIRAL VACCINES			\$148,559	\$0.16	116.3%	22.9	119.9%	\$82.2	-1.7%
TRONVITE	B-COMPLEX W/ C & FOLIC ACID			\$174,915	\$0.18	-81.2%	1.2	-81.1%	\$1,880.8	-0.3%
INGREZZA	MOVEMENT DISORDER DRUG THERAPY		Y	\$57,918	\$0.06	76.5%	0.1	68.3%	\$5,791.8	4.8%
AZITHROMYCIN	AZITHROMYCIN	Y		\$73,664	\$0.08	75.0%	110.7	52.5%	\$8.4	14.7%
AFINITOR	ANTINEOPLASTIC - MTOR KINASE INHIBITORS		Y	\$149,750	\$0.16	72.0%	0.1	68.3%	\$14,975.0	2.1%
ONFI	ANTICONSULSANTS - BENZODIAZEPINES		Y	\$90,857	\$0.10	-66.9%	0.7	-66.1%	\$1,539.9	-2.3%
CEFdinir	CEPHALOSPORINS - 3RD GENERATION	Y		\$194,919	\$0.21	65.8%	68.0	49.7%	\$36.3	10.8%
ALBUTEROL SULFATE	BETA ADRENERGICS	Y	Y	\$82,374	\$0.09	64.9%	65.1	45.6%	\$16.0	13.3%
TRELEGY ELLIPTA	ADRENERGIC COMBINATIONS		Y	\$49,849	\$0.05	54.8%	1.2	51.5%	\$519.3	2.2%
VPRIV	AGENTS FOR GAUCHER DISEASE		Y	\$133,258	\$0.14	51.5%	0.0	51.5%	\$44,419.2	0.0%
AMOXICILLIN	AMINOPENICILLINS	Y		\$93,068	\$0.10	49.6%	223.1	40.8%	\$5.3	6.2%



# Savings Opportunities


## Pharmacy Analytics Report

Reporting Period: October 2018 to December 2018

Generic formulations, when available, can be significantly less expensive and just as effective as brand name medications. In this section we review the proportion of branded versus generic drug prescriptions dispensed for this population and look for cost savings opportunities where substitutes exist for often-prescribed brand name medications.


### Drug Mix

#### % of Total PMPM by Drug Type



The Generic Prescribing Rate for this population is 85.2%, which is higher than the benchmark rate of 80%. Opportunities for specific medications are detailed below.

#### Generic Prescribing Rate by Rolling 12 Month Period



**Top 25 Generic Substitution Opportunities**

Drug name (Brand)	Top 25 Opportunities  ■ Substitute Costs ■ Added Brand Costs	Paid (In 1,000)	Scripts per K	Substitute	Savings Opportunity	
					In 1,000	%
ONFI		\$90.9	0.7	CLOBAZAM	\$43.3	47.6%
KEPPRA		\$20.3	0.3	LEVETIRACETAM	\$16.4	80.8%
LAMICTAL		\$18.9	0.2	LAMOTRIGINE	\$16.1	85.3%
KEPPRA XR		\$19.4	0.2	LEVETIRACETAM ER	\$15.7	80.7%
LAMICTAL XR		\$14.2	0.1	LAMOTRIGINE ER	\$10.1	71.7%
SYNTHROID		\$15.2	5.2	LEVOTHYROXINE SODIUM	\$8.0	52.8%
EPIPEN JR 2-PAK		\$17.7	0.4	EPINEPHRINE	\$7.9	44.8%
TOPAMAX		\$9.1	0.1	TOPIRAMATE	\$7.8	85.3%
AMPYRA		\$12.1	0.1	DALFAMPRIDINE ER	\$6.0	49.2%
ABILIFY		\$8.1	0.1	ARIPIRAZOLE	\$5.8	72.1%
OXYCONTIN		\$18.0	0.5	OXYCODONE HCL ER	\$5.7	32.0%
PREPLUS		\$9.9	6.8	PRENATAL PLUS	\$5.6	56.6%
DEXEDRINE		\$6.1	0.1	DEXTROAMPHETAMINE SULFATE ER	\$5.4	89.4%
COPAXONE		\$52.9	0.1	GLATIRAMER ACETATE	\$4.7	8.9%
LOTRONEX		\$8.2	0.0	ALOSETRON HCL	\$4.7	57.1%
TRILEPTAL		\$5.6	0.1	OXCARBAZEPINE	\$4.5	81.1%
SEROQUEL XR		\$7.6	0.1	QUETIAPINE FUMARATE ER	\$4.3	56.7%
DEPAKOTE		\$5.2	0.1	DIVALPROEX SODIUM	\$3.9	76.3%
GEODON		\$4.0	0.0	ZIPRASIDONE HCL	\$3.8	94.3%
DILANTIN		\$5.5	0.6	PHENYTOIN SODIUM EXTENDED	\$3.5	64.2%
ZONEGRAN		\$4.0	0.1	ZONISAMIDE	\$3.1	77.4%
NUVIGIL		\$4.4	0.1	ARMODAFINIL	\$3.0	68.3%
EFFEXOR XR		\$3.4	0.1	VENLAFAXINE HCL ER	\$3.0	86.0%
INTUNIV		\$4.1	0.2	GUANFACINE HCL ER	\$2.7	65.4%
STRATTERA		\$4.4	0.1	ATOMOXETINE HCL	\$2.6	58.9%



In addition to the overall generic prescribing rate (GPR) for this population, we evaluate GPRs for individual providers to identify potential opportunities.


### Top 25 Prescribers by Generic Savings Opportunity

Prescribing Physician	Prescribing					Opportunity		
	Total Paid	Paid per Script	Total Scripts	# of Unique Members	Generic Prescribing Rate	Scripts with Generic Substitution	Scripts Needed to meet Target	Savings Opportunity
SKJEI, KAREN	\$172,255	\$775.9	222	34	74.3%	25	13	\$10,376
SHAFER, CHRISTOPHER	\$76,594	\$296.9	258	41	76.7%	24	9	\$9,796
WOODS, REBEKAH	\$31,071	\$393.3	79	18	69.6%	9	9	\$6,014
CORWIN, HAL	\$14,807	\$370.2	40	7	50.0%	7	12	\$2,639
GANESH, GEETA	\$186,477	\$1,922.4	97	23	76.3%	4	4	\$2,360
TUMKUR, AMBICA	\$24,029	\$358.6	67	23	77.6%	5	2	\$2,237
OWENS, JOSEPH	\$25,465	\$530.5	48	22	72.9%	3	4	\$1,780
LEE, DANIEL	\$37,913	\$881.7	43	10	65.1%	3	7	\$1,760
TURBYVILLE, JOSEPH	\$73,741	\$105.8	697	195	75.8%	10	30	\$1,668
ANDERSON, GREG	\$18,314	\$872.1	21	4	76.2%	3	1	\$1,440
ALREFAI, HISHAM	\$365,546	\$341.0	1,072	210	44.6%	49	380	\$1,221
TURNER, MICHELE	\$5,625	\$165.4	34	4	76.5%	1	2	\$847
VAUGHAN, POLLY	\$1,494	\$373.5	4	2	75.0%	1	1	\$689
CAROSELLA, CHRISTOPHER	\$1,453	\$1,452.6	1	1	0.0%	1	1	\$689
DENZIK, CHERYL	\$1,085	\$120.5	9	1	66.7%	3	2	\$652
THORNBURY, AMY	\$4,972	\$155.4	32	11	78.1%	3	1	\$602
KORSON, RACHEL	\$6,949	\$496.4	14	5	71.4%	1	2	\$594
JHAMB, INDAR	\$4,352	\$53.7	81	13	76.5%	3	3	\$580
MOKA, NAGABHISHEK	\$2,513	\$109.3	23	1	65.2%	4	4	\$577
CORBETT, MARK	\$20,880	\$68.9	303	108	70.3%	2	30	\$574
IQBAL, MOHAMMAD	\$5,662	\$246.2	23	14	73.9%	1	2	\$573
COYLE, DAMON	\$32,986	\$84.1	392	121	76.8%	11	13	\$556
SUBLETT, JAMES	\$75,342	\$79.1	952	223	75.7%	24	41	\$556
POLLARD, STEPHEN	\$46,242	\$79.7	580	129	77.4%	5	15	\$548
CAVALLAZZI, RODRIGO	\$17,194	\$175.4	98	21	42.9%	1	37	\$547

## Medication Adherence Pharmacy Analytics Report


Reporting Period: October 2018 to  
December 2018

Measuring medication adherence can help identify missed doses and prevent future medical complications, especially for members with high impact conditions such as asthma, high cholesterol, hypertension, diabetes, HIV and behavioral health conditions. A standard approach of measuring medication adherence is with a metric known as Percent (or Proportion) of Days Covered, or PDC. At a high level, PDC represents the fraction of days in a year during which the member "took" their medication (as approximated by their pattern of medication fill dates).



Condition	Members	Members with PDC >= 80%	Mean PDC	Mean Risk		Risk-Adjusted PMPM		Inpatient/1000		ED/1000	
				Target Met	Target Missed	Target Met	Target Missed	Target Met	Target Missed	Target Met	Target Missed
				Asthma	14,932	35.1%	61.7%	3.7	2.7	\$286.7	\$215.4
Behavioral Health	44,902	48.8%	70.7%	3.6	3.0	\$305.3	\$273.3	244.6	244.5	1,147.7	1,392.5
Cholesterol	16,503	60.2%	78.6%	3.8	3.5	\$305.0	\$284.3	293.2	324.2	810.1	1,146.8
Diabetes	7,563	57.7%	76.8%	3.5	3.2	\$284.7	\$233.7	251.3	219.1	798.8	1,055.9
HIV	537	43.4%	66.8%	5.6	5.0	\$506.9	\$388.7	215.0	572.9	723.1	1,974.9
Hypertension	21,141	60.9%	78.7%	3.3	3.3	\$301.8	\$269.2	262.7	319.1	823.5	1,249.3

This graph compares the risk-adjusted PMPMs for members meeting compliance (80% PDC) and members below the target. The top ovals show percent differences between the two groups.



The tables below compare the risk scores, PMPM, and utilization metrics for members meeting the 80% PDC rate and those who missed the target.

Medication Adherence for Top 10 GPI6s by Member Volume												
Drug Subclass (GPI6)	Members	Members with PDC >= 80%	Mean PDC	% of Maintenance Drugs	Mean Risk		Risk-Adjusted PMPM		Inpatient/1000		ED/1000	
					Target Met	Target Missed	Target Met	Target Missed	Target Met	Target Missed	Target Met	Target Missed
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)	13,854	60.5%	79.0%	2.1%	3.5	2.8	\$343.9	\$296.3	245.7	223.1	1185.8	1443.6
NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS)	13,574	57.5%	76.2%	3.8%	3.5	2.9	\$370.6	\$316.7	282.0	277.0	1423.9	1911.1
ANTIHISTAMINES - NON-SEDATING	11,060	59.1%	76.9%	0.1%	3.7	2.7	\$349.6	\$257.3	242.5	147.8	1119.2	1267.9
ANTICONVULSANTS - MISC.	10,079	68.5%	82.7%	3.0%	4.5	4.0	\$370.0	\$314.6	376.3	319.0	1360.7	1645.5
PROTON PUMP INHIBITORS	9,920	69.8%	83.1%	1.0%	4.3	3.9	\$364.9	\$324.0	385.1	385.5	1300.2	1820.7
BETA ADRENERGICS	9,841	57.0%	75.5%	0.3%	4.3	3.2	\$362.7	\$283.1	361.1	262.0	1425.5	1705.4
CENTRAL MUSCLE RELAXANTS	8,501	65.0%	80.3%	0.7%	4.1	3.4	\$390.3	\$322.8	355.6	288.0	1522.5	2246.5
GLUCOCORTICOSTEROIDS	7,916	56.1%	75.0%	0.0%	4.1	3.3	\$376.8	\$314.5	397.0	317.6	1852.8	2229.9
HYDROCODONE COMBINATIONS	6,659	63.2%	78.9%	0.0%	4.5	3.7	\$437.0	\$365.0	522.7	421.3	1663.3	2121.6
AMINOPENICILLINS	4,971	49.7%	71.3%	0.0%	3.6	2.7	\$343.8	\$240.6	263.6	171.2	1436.6	1593.2


Medication Adherence for Top 10 PCPs by % Non-Adherent Members (min 10 members)												
PCP	Members	Members with PDC >= 80%	Mean PDC	Mean Risk		Risk-Adjusted PMPM		Inpatient/1000		ED/1000		
				Target Met	Target Missed	Target Met	Target Missed	Target Met	Target Missed	Target Met	Target Missed	
AGAPE HEALTH CENTER	10	4.2%	55.7%	1.2	3.6	\$0.0	\$508.4	-	-	-	-	3,130.4
NEWBORN KIDS HEALTH CENTER INC	21	4.9%	41.3%	7.5	2.2	\$492.7	\$123.4	-	-	-	-	827.6
FAMILY PRACTICE OF KENTUCKY LLC	15	7.4%	54.7%	6.0	3.0	\$2,025.3	\$1,160.6	-	480.0	-	-	2,400.0
TRI STATE PEDIATRICS	14	7.5%	47.1%	6.2	2.8	\$6.4	\$156.0	-	-	-	-	324.3
BAKER, BRENDA	11	9.1%	52.1%	2.0	4.0	\$97.5	\$1,192.3	-	1,200.0	-	-	800.0
ROCKCASTLE PEDIATRICS & ADOLESCENTS	11	9.4%	54.5%	2.8	2.1	\$0.0	\$390.2	-	413.8	-	-	2,482.8
PRIMARY CARE CENTERS OF EASTERN KY HINDMAN	11	10.3%	68.3%	2.0	2.4	\$605.8	\$807.6	-	-	4,000.0	-	1,384.6
KID CARE PSC	20	10.9%	45.3%	4.1	1.8	\$321.0	\$166.0	-	-	-	-	734.7
BRIGHT FUTURE PRIMARY CARE	18	11.5%	46.7%	1.1	4.5	\$0.0	\$552.7	-	-	-	-	1,304.3
GHAYTH M HAMMAD MD PSC	36	11.7%	59.4%	2.4	2.6	\$1,017.7	\$238.1	1,000.0	131.9	-	-	263.7




The Evolent Pharmacy Team created flags to monitor potential Fraud, Waste, and Abuse (FWA) by pharmacies and members. Flags for pharmacies are described in Appendix A.

Top 25 Pharmacies by FWA Flags and Total Paid														
Pharmacy	City	State	Total Scripts	Total Paid	Total Flags	Individual Flags								
						Cost per Member	Claims per Member	Claims per Presc.	Cost per Script	GDR	Hi Control Sub.	Hi Vol. Drug	Hi Vol. Presc.	
ACCREDITO HEALTH GROUP	WARRENDALE	PA	42	\$382,828	5	1	0	0	1	1	0	1	1	
CURANT HEALTH FLORIDA	ST PETERSBURG	FL	111	\$61,657	5	1	1	0	1	1	0	0	1	
MEDICINE ARTS PHARMAC	BOWLING GREEN	KY	445	\$52,199	5	1	0	0	1	0	1	1	1	
JOHNS CREEK DRUG CENT	PIKEVILLE	KY	264	\$32,628	5	1	0	0	1	0	1	1	1	
COORDINATED CARE NETV	PITTSBURGH	PA	38	\$24,767	5	1	1	0	1	1	0	0	1	
PHARMERICA 7059	GLASGOW	KY	182	\$21,925	5	1	1	0	1	1	0	0	1	
SEMC MEDICAL VILLAGE P	EDGEWOOD	KY	69	\$20,372	5	1	0	0	1	0	1	1	1	
DUNCAN SPECIALTY PHAR	MAYFIELD	KY	393	\$1,002,266	4	1	0	0	1	1	0	1	0	
HCTC PHARMACY	LOUISVILLE	KY	75	\$999,838	4	1	0	0	1	0	0	1	1	
BRIOVARX	FRANKLIN	TN	55	\$699,697	4	1	0	0	1	1	0	1	0	
CAREMARK SPECIALTY 480	MT PROSPECT	IL	111	\$587,376	4	1	0	0	1	1	0	1	0	
ST MATTHEWS SPECIALTY	LOUISVILLE	KY	257	\$475,928	4	1	0	0	1	1	0	1	0	
MAGELLAN RX PHARMACY	ORLANDO	FL	62	\$421,633	4	1	0	0	1	1	0	1	0	
ACCREDITO HEALTH GROUP	MEMPHIS	TN	74	\$399,247	4	1	0	0	1	1	0	1	0	
PREMIER KIDS CARE INC	HOLLYWOOD	FL	95	\$375,508	4	1	0	0	1	0	0	1	1	
CYSTIC FIBROSIS SERVICES	FRISCO	TX	28	\$267,167	4	1	0	0	1	1	0	0	1	
ARH COMMUNITY PHARM	HAZARD	KY	103	\$219,966	4	1	0	0	1	1	0	0	1	
NPS PHARMACY	PADUCAH	KY	88	\$81,531	4	1	0	0	1	1	0	0	1	
EXACT CARE PHARMACY L	CLEVELAND	OH	701	\$74,757	4	1	1	0	1	1	0	0	0	
COMMUNITY A WALGREEN	LEXINGTON	KY	34	\$54,739	4	1	0	0	1	1	0	0	1	
KING PHARMACY INC	HAZARD	KY	755	\$50,804	4	1	1	0	0	0	1	1	0	
GEORGETOWN APOTHECA	GEORGETOWN	KY	497	\$38,380	4	0	1	0	0	0	1	1	1	
TOTAL PHARMACY CARE 4	MARTIN	KY	665	\$30,083	4	0	1	0	0	0	1	1	1	
J & L PHARMACY	GEORGETOWN	KY	280	\$29,334	4	1	1	0	1	1	0	0	0	
STANTON DRUGS	STANTON	KY	502	\$25,305	4	0	1	0	0	0	1	1	1	

Member-level FWA flags are described in Appendix B. There are 647,124 eligible members in this population without any FWA flags while 1% of members have at least one flag.



Members for Each FWA Flag






Opioid abuse continues as a major public health issue in the United States. In this section we examine the top prescribed opioids for this population, the most commonly associated 3-digit diagnosis for each drug, and the geographic distribution of members taking opioids.

Top 25 Opioids by Total Paid

Opioid Name	Drug Class (GPI 4)	Total Scripts	Total Paid	Paid/Script	IP within 30 days/1000	IP Relative Rate	ED within 30 days /1000	ED Relative Rate	Most Prescribing Pharmacy		Most Prescribing Provider	
									Name	% of Total Paid	Name	% of Total Paid
BUPRENORPHINE-NALOXONE	OPIOID PARTIAL AGONISTS	30,578	\$2,751,028	\$90.0	50.5	0.4	280.0	0.3	EAST KENTUCKY D	1.4%	ISMAIL, ASAD	2.0%
HYDROCODONE-ACETAMINOPHENE	OPIOID COMBINATIONS	16,401	\$284,520	\$17.3	129.2	0.9	588.8	0.7	WALGREENS 037	2.9%	JACKSON, JAMES	3.7%
OXYCODONE-ACETAMINOPHENE	OPIOID COMBINATIONS	5,125	\$164,415	\$32.1	163.6	1.1	607.5	0.8	WALGREENS 037	1.6%	JACKSON, JAMES	5.0%
SUBOXONE	OPIOID PARTIAL AGONISTS	162	\$36,564	\$225.7	52.3	0.4	209.2	0.3	MEDICINE STOP P	7.3%	GAMMON, DAVID	10.0%
BUPRENORPHINE HCL	OPIOID PARTIAL AGONISTS	897	\$30,130	\$33.6	478.1	3.3	403.9	0.5	NICHOLS APOTHE	5.0%	BIRCH, MORGAN	3.9%
OXYCONTIN	OPIOID AGONISTS	73	\$29,962	\$410.4	78.4	0.5	235.3	0.3	KROGER PHARMA	8.3%	VERGHIS, ARUL	9.7%
SUBLOCADE	OPIOID PARTIAL AGONISTS	16	\$25,434	\$1,589.6	0.0	0.0	266.7	0.3	ACCREDO HEALTH	62.5%	BANKS, ADRIAN	25.0%
OXYCODONE HCL	OPIOID AGONISTS	1,137	\$23,242	\$20.4	336.4	2.4	672.8	0.8	KENTUCKY CLINI	3.4%	JACKSON, JAMES	3.5%
BUPRENORPHINE	OPIOID PARTIAL AGONISTS	25	\$11,056	\$442.3	0.0	0.0	571.4	0.7	HAZARD ARH REG	38.3%	LALONDE, DANIE	34.5%
NUCYNTA	OPIOID AGONISTS	15	\$10,743	\$716.2	0.0	0.0	1,142.9	1.4	ANDREWS PHARM	19.1%	BARNETT, DAREL	34.1%
OXYCODONE HCL ER	OPIOID AGONISTS	33	\$10,360	\$313.9	607.6	4.3	1,063.3	1.3	COX'S VARIETY &	22.4%	PETERS, LAWREN	22.4%
TRAMADOL HCL	OPIOID AGONISTS	2,149	\$8,303	\$3.9	115.2	0.8	813.8	1.0	WALGREENS 136	2.2%	BASHAM, RICHAR	2.1%
MORPHINE SULFATE ER	OPIOID AGONISTS	196	\$8,081	\$41.2	373.2	2.6	373.2	0.5	U OF L HOSP AMB	6.2%	VERGHIS, ARUL	9.2%
ACETAMINOPHEN-CODEINE	OPIOID COMBINATIONS	857	\$8,071	\$9.4	106.1	0.7	860.5	1.1	MIDWAY PHARM	5.7%	BASHAM, RICHAR	7.6%
FENTANYL	OPIOID AGONISTS	98	\$7,819	\$79.8	275.2	1.9	550.5	0.7	WALGREENS 037	2.1%	PIERCE, SCOTT	14.2%
TRAMADOL HCL ER	OPIOID AGONISTS	58	\$5,494	\$94.7	206.9	1.4	206.9	0.3	KROGER PHARMA	12.4%	BAKER, ROBERT	6.5%
METHADONE HCL	OPIOID AGONISTS	122	\$2,999	\$24.6	183.9	1.3	367.8	0.5	PAT'S PHARMACY	6.4%	VERGHIS, ARUL	15.0%
OXYMORPHONE HCL ER	OPIOID AGONISTS	7	\$2,625	\$375.0	0.0	0.0	800.0	1.0	EASTRIDGE-PHEL	44.0%	LEDFORD, MELAN	50.2%
BUTRANS	OPIOID PARTIAL AGONISTS	4	\$2,566	\$641.5	0.0	0.0	1,000.0	1.2	RITE VALUE PHAR	56.1%	HANSEN, ZACHAR	56.1%
EMBEDA	OPIOID AGONISTS	4	\$2,432	\$608.1	0.0	0.0	0.0	0.0	WALGREENS 022	100.0%	VERGHIS, ARUL	100.0%
XTAMPZA ER	OPIOID AGONISTS	5	\$1,999	\$399.8	0.0	0.0	0.0	0.0	C&C PHARMACY	54.5%	LEDFORD, MELAN	54.5%
MORPHINE SULFATE	OPIOID AGONISTS	43	\$1,860	\$43.3	642.9	4.5	428.6	0.5	HUME PHARMAC	21.7%	STACY, DONNIE	10.7%
BUTORPHANOL TARTRATE	OPIOID PARTIAL AGONISTS	58	\$1,785	\$30.8	166.7	1.2	500.0	0.6	PAT'S PHARMACY	17.0%	ANGELES, VICTOR	26.6%
ZUBSOLV	OPIOID PARTIAL AGONISTS	17	\$1,653	\$97.2	0.0	0.0	1,411.8	1.7	APOTHECARE PHA	44.1%	JOHNSON, JOYCE	29.9%
OXYAYDO	OPIOID AGONISTS	2	\$1,610	\$804.9	0.0	0.0	0.0	0.0	YOUR HOMETOW	100.0%	KIJEWski, KONRA	100.0%




Most Common Diagnosis for Top 25 Opioids by Total Paid							
Opioid Name	Drug Class (GPI 4)	3-Digit Dx Code	Dx Description	Total Scripts for Dx	% of Total Scripts	Total Paid for Dx	% of Total Paid
BUPRENORPHINE-NALOXONE	OPIOID PARTIAL AGONISTS	F11	OPIOID RELATED DISORDERS	27,290	89.2%	\$2,400,170	87.2%
HYDROCODONE-ACETAMINOPHEN	OPIOID COMBINATIONS	M54	DORSALGIA	1,646	10.0%	\$33,883	11.9%
OXYCODONE-ACETAMINOPHEN	OPIOID COMBINATIONS	M54	DORSALGIA	478	9.3%	\$20,871	12.7%
SUBOXONE	OPIOID PARTIAL AGONISTS	F11	OPIOID RELATED DISORDERS	139	85.8%	\$31,494	86.1%
BUPRENORPHINE HCL	OPIOID PARTIAL AGONISTS	F11	OPIOID RELATED DISORDERS	734	81.8%	\$23,776	78.9%
OXYCONTIN	OPIOID AGONISTS	M51	THORACIC, THORACOLUM, AND LUMBOSACRAL INTVRT	7	9.6%	\$1,800	6.0%
SUBLOCADE	OPIOID PARTIAL AGONISTS	F11	OPIOID RELATED DISORDERS	5	31.3%	\$7,949	31.3%
OXYCODONE HCL	OPIOID AGONISTS	G89	PAIN, NOT ELSEWHERE CLASSIFIED	104	9.1%	\$2,331	10.0%
BUPRENORPHINE	OPIOID PARTIAL AGONISTS	M54	DORSALGIA	6	24.0%	\$2,684	24.3%
NUCYNTA	OPIOID AGONISTS	G89	PAIN, NOT ELSEWHERE CLASSIFIED	4	26.7%	\$4,079	38.0%
OXYCODONE HCL ER	OPIOID AGONISTS	Z51	ENCOUNTER FOR OTHER AFTERCARE AND MEDICAL CAR	5	15.2%	\$1,593	15.4%
TRAMADOL HCL	OPIOID AGONISTS	M54	DORSALGIA	203	9.4%	\$758	9.1%
MORPHINE SULFATE ER	OPIOID AGONISTS	Z51	ENCOUNTER FOR OTHER AFTERCARE AND MEDICAL CAR	28	14.3%	\$1,193	14.8%
ACETAMINOPHEN-CODEINE	OPIOID COMBINATIONS	M54	DORSALGIA	71	8.3%	\$701	8.7%
FENTANYL	OPIOID AGONISTS	Z51	ENCOUNTER FOR OTHER AFTERCARE AND MEDICAL CAR	21	21.4%	\$1,659	21.2%
TRAMADOL HCL ER	OPIOID AGONISTS	M54	DORSALGIA	4	6.9%	\$435	7.9%
METHADONE HCL	OPIOID AGONISTS	Z79	LONG TERM (CURRENT) DRUG THERAPY	19	15.6%	\$551	18.4%
OXYMORPHONE HCL ER	OPIOID AGONISTS	G89	PAIN, NOT ELSEWHERE CLASSIFIED	2	28.6%	\$935	35.6%
BUTRANS	OPIOID PARTIAL AGONISTS	M46	OTHER INFLAMMATORY SPONDYLOPATHIES	2	50.0%	\$1,127	43.9%
EMBEDA	OPIOID AGONISTS	Z23	ENCOUNTER FOR IMMUNIZATION	1	25.0%	\$608	25.0%
XTAMPZA ER	OPIOID AGONISTS	G89	PAIN, NOT ELSEWHERE CLASSIFIED	3	60.0%	\$1,181	59.1%
MORPHINE SULFATE	OPIOID AGONISTS	Z51	ENCOUNTER FOR OTHER AFTERCARE AND MEDICAL CAR	9	20.9%	\$652	35.1%
BUTORPHANOL TARTRATE	OPIOID PARTIAL AGONISTS	J30	VASOMOTOR AND ALLERGIC RHINITIS	8	13.8%	\$241	13.5%
ZUSOLV	OPIOID PARTIAL AGONISTS	F11	OPIOID RELATED DISORDERS	17	100.0%	\$1,653	100.0%
OXYAYDO	OPIOID AGONISTS	M54	DORSALGIA	2	100.0%	\$1,610	100.0%



**Patient Safety**  
Pharmacy Analytics Report

Reporting Period: October 2018 to  
December 2018

Members taking multiple medications that could interact with each other can lead to serious adverse health outcomes. This section focuses on members with two or more unique drugs filled in the last 90 days and reports the volume of drug-drug interactions by month. It also provides additional details on the most recent 25 interactions.



**Top 25 Interactions by Most Recent Interaction Date**

Severity	Interaction	Index Drug	Index Prescriber	Index Prescribing Date	Index Supply	Interacting Drug	Interacting Prescriber	Interacting Prescribing Date	Interacting Supply	Overlapping Supply
Moderate Interaction	NON-CARDIOSELECTIVE BETA-BLOCKERS/BETA-2 AGONISTS	NADOLOL	VERTREES, KIMBERLY	11/7/18	90	VENTOLIN HFA	BOSLEY, JEANETTA	12/31/18	30	30
Moderate Interaction	CIMETIDINE; RANITIDINE/HYDANTOINS	RANITIDINE HCL	DEPREST, BRIAN	10/30/18	90	PHENYTOIN SODIUM EXTENDED	DEPREST, BRIAN	12/31/18	30	28
Moderate Interaction	SELECTED BETA-BLOCKERS/SELECTED CALCIUM CHANNEL BLOCKERS	METOPROLOL SUCCINATE	RYLE, LARRY	10/20/18	90	CARTIA XT	SHELTON, DAVID	12/31/18	30	18
Moderate Interaction	METOPROLOL/SELECTED CYP2D6 INHIBITORS	METOPROLOL SUCCINATE	NUNAMAKER, JACOB	11/8/18	90	SERTRALINE HCL	BROWN, JERILYN	12/31/18	30	30
Severe Interaction	ACE INHIBITORS; ARBS/TRIMETHOPRIM	LISINAPRIL	VALAYAM, JOSEPH	10/21/18	90	SULFAMETHOXAZOLE-TRIMETHOP	COFFIE, RAMONA	12/31/18	30	19
Moderate Interaction	SELECTED ACE INHIBITORS/TIZANIDINE	LISINAPRIL	HAMILTON, CICELY	10/24/18	90	TIZANIDINE HCL	KEAN, DANIEL	12/31/18	30	22
Severe Interaction	SELECTED PLATELET AGGREGATION INHIBITORS/NSAIDS	CLOPIDOGREL	MARANO, ANTHONY	10/24/18	90	MELOXICAM	PRESTON, HENRY	12/31/18	30	22
Moderate Interaction	CLOPIDOGREL/SELECTED SSRI; SNRI	CLOPIDOGREL	MARANO, ANTHONY	10/24/18	90	SERTRALINE HCL	PRESTON, HENRY	12/31/18	30	22
Moderate Interaction	ACE INHIBITORS/SELECTED NSAIDS	LISINAPRIL	FINEMAN, LARRY	10/22/18	90	IBUPROFEN	MARTIN, JAMES	12/31/18	30	20
Moderate Interaction	ACE INHIBITORS; ARBS/LOOP DIURETICS	LOSARTAN POTASSIUM	HILL, JOSH	10/29/18	90	FUROSEMIDE	HILL, JOSH	12/31/18	90	27
Moderate Interaction	BETA-BLOCKERS/NONSTEROIDAL ANTI-INFLAMMATORY DRUGS	NADOLOL	VERTREES, KIMBERLY	11/7/18	90	IBUPROFEN	BOSLEY, JEANETTA	12/31/18	30	30
Moderate Interaction	THIAZIDES/ANTI-DIABETICS	HYDROCHLOROTHIAZIDE	TAYLOR, SANDRA	11/5/18	90	GLIPIZIDE ER	TAYLOR, SANDRA	12/31/18	45	34
Moderate Interaction	THYROID PREPS/ORAL CALCIUM ACETATE; CARBONATE; CITRATE	LEVOTHYROXINE SODIUM	MCCARTY, WENDY	10/30/18	90	CALCIUM 600-VIT D3	MCCARTY, WENDY	12/31/18	30	28
Moderate Interaction	LOOP DIURETICS/ACE INHIBITORS; ARBS	FUROSEMIDE	MERRITT, EMILY	10/29/18	90	LISINAPRIL	MERRITT, EMILY	12/31/18	30	27
Moderate Interaction	SELECTED ANTIHYPERTENSIVES/TIZANIDINE	FUROSEMIDE	PATEL, VIRAL	11/16/18	90	TIZANIDINE HCL	GRAINGER, JONATHAN	12/31/18	19	19
Moderate Interaction	SELECTED ACE INHIBITORS/POTASSIUM SPARING DIURETICS	LISINAPRIL	ARLA, MOHANA	10/23/18	90	SPIRONOLACTONE	ARLA, MOHANA	12/31/18	30	21
Moderate Interaction	BETA-BLOCKERS/NONSTEROIDAL ANTI-INFLAMMATORY DRUGS	METOPROLOL SUCCINATE	MARTENS, JAMIE	11/3/18	90	MELOXICAM	MARTENS, JAMIE	12/31/18	30	30
Moderate Interaction	THYROID PREPARATIONS/ESTROGENS	LEVOTHYROXINE SODIUM	GOTTSCHALK, GINNY	11/9/18	90	ESTRADIOL	HAGER, WILLIAM	12/31/18	30	30
Moderate Interaction	THYROID PREPS/ORAL CALCIUM ACETATE; CARBONATE; CITRATE	LEVOTHYROXINE SODIUM	BARNES, CHERYL	10/24/18	90	OYSTER SHELL CALCIUM-VIT D3	BARNES, CHERYL	12/31/18	25	22
Severe Interaction	NSAIDS/SELECTED ANTICOAGULANTS (VIT K ANTAGONISTS)	MELOXICAM	GABIS, CHARLES	11/12/18	90	WARFARIN SODIUM	GABIS, CHARLES	12/31/18	30	30
Moderate Interaction	NON-CARDIOSELECTIVE BETA-BLOCKERS/BETA-2 AGONISTS	NADOLOL	VERTREES, KIMBERLY	11/7/18	90	BREO ELLIPTA	BOSLEY, JEANETTA	12/31/18	30	30
Moderate Interaction	SELECTED ANTIHYPERTENSIVES/TIZANIDINE	FUROSEMIDE	MERRITT, EMILY	10/29/18	90	TIZANIDINE HCL	MERRITT, EMILY	12/31/18	30	27
Moderate Interaction	METOPROLOL/SELECTED CYP2D6 INHIBITORS	METOPROLOL SUCCINATE	HUANG, ANNA	10/24/18	90	PAROXETINE HCL	CAUDILL, ROBERT	12/31/18	30	22
Moderate Interaction	ANGIOTENSIN II RECEPTOR BLOCKER (ARB)/NSAIDS	LOSARTAN-HYDROCHLOROTHIAZIDE	HARVEY, JACOB	11/16/18	90	NAPROXEN	HARVEY, JACOB	12/31/18	30	30
Moderate Interaction	SELECTED ACE INHIBITORS/POTASSIUM SPARING DIURETICS	LISINAPRIL	FAHSAH, IBRAHIM	10/29/18	90	SPIRONOLACTONE	FAHSAH, IBRAHIM	12/31/18	30	27




The following chart and table describe the relationship between drug and condition. It is important to understand the same drug can be prescribed for multiple conditions and that patients with comorbidities could be taking multiple drugs that could potentially lead to unfavorable interactions. The tile chart below shows the percentage of members with the chronic condition who are prescribed medication from the displayed drug class; percentages may sum to more than 1.

### Most Commonly Prescribed ETCs for Select Conditions

(minimum prescribed rate of 5% for each condition)

■ Diabetes ■ Asthma ■ CHF ■ COPD ■ Hypertension



### Top 100 3-Digit Diagnosis to Drug Relationships

3-Digit Diagnosis	Drug	Enhanced Therapeutic Classification (ETC)	% of Drug-Condition Overlap*	Diagnosis Prevalence per 1,000	Drug Paid PMPM	Drug Scripts per 1,000	Paid per Script	Prescribed % of ETC	Generic Indicator	Maintenance Indicator
F11 - OPIOID RELATED DISORDERS	BUPRENORPHINE-NALOXONE	Agents for Opioid Withdrawal, Opioid-Type	74.2%	2007.0	\$2.90	386.9	\$90.0	96.6%	Y	Y
J09 - INFLUENZA DUE TO CERTAIN IDENTIFIED INFLUENZA VIRUSES	OSELTAMIVIR PHOSPHATE	Influenza Antiviral Agents - Neuraminidase Inhibitors	46.5%	19.3	\$0.24	24.9	\$116.3	100.0%	Y	N
J11 - INFLUENZA DUE TO UNIDENTIFIED INFLUENZA VIRUS	OSELTAMIVIR PHOSPHATE	Influenza Antiviral Agents - Neuraminidase Inhibitors	43.0%	18.6	\$0.24	24.9	\$116.3	100.0%	Y	N
J10 - INFLUENZA DUE TO OTHER IDENTIFIED INFLUENZA VIRUS	OSELTAMIVIR PHOSPHATE	Influenza Antiviral Agents - Neuraminidase Inhibitors	41.7%	51.8	\$0.24	24.9	\$116.3	100.0%	Y	N
K01 - EMBEDDED AND IMPACTED TEETH	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	39.8%	23.6	\$0.30	207.5	\$17.3	99.9%	Y	N
L01 - IMPETIGO	MUPIROCI	Dermatological - Antibacterial Other	34.5%	10.4	\$0.04	27.5	\$17.1	100.0%	Y	N
O80 - ENCOUNTER FOR FULL-TERM UNCOMPLICATED DELIVERY	IBUPROFEN	NSAID Analgesics (COX Non-Specific) - Propionic Acid Derivatives	32.9%	18.9	\$0.09	189.1	\$6.0	67.1%	Y	Y
B37 - CANDIDIASIS	FLUCONAZOLE	Antifungal - Triazoles	32.1%	30.8	\$0.04	62.7	\$6.2	98.9%	Y	N
K81 - CHOLECYSTITIS	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	31.1%	9.2	\$0.30	207.5	\$17.3	99.9%	Y	N
Z79 - LONG TERM (CURRENT) DRUG THERAPY	BUPRENORPHINE-NALOXONE	Agents for Opioid Withdrawal, Opioid-Type	30.6%	462.5	\$2.90	386.9	\$90.0	96.6%	Y	Y
G62 - OTHER AND UNSPECIFIED POLYNEUROPATHIES	GABAPENTIN	Anticonvulsant - GABA Analogs	30.2%	14.4	\$0.21	229.4	\$11.1	96.5%	Y	Y
K35 - ACUTE APPENDICITIS	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	29.7%	11.1	\$0.30	207.5	\$17.3	99.9%	Y	N
N76 - OTHER INFLAMMATION OF VAGINA AND VULVA	METRONIDAZOLE	Antiprotozoal-Antibacterial 1st Generation 2-methyl-5-nitroimidazole	29.4%	59.8	\$0.03	35.5	\$9.4	100.0%	Y	N
H66 - SUPPURATIVE AND UNSPECIFIED OTITIS MEDIA	AMOXICILLIN	Aminopenicillin Antibiotic	29.3%	204.5	\$0.10	223.1	\$5.3	99.8%	Y	N
N89 - OTHER NONINFLAMMATORY DISORDERS OF VAGINA	METRONIDAZOLE	Antiprotozoal-Antibacterial 1st Generation 2-methyl-5-nitroimidazole	27.1%	96.5	\$0.03	35.5	\$9.4	100.0%	Y	N
I21 - ACUTE MYOCARDIAL INFARCTION	ATORVASTATIN CALCIUM	Antihyperlipidemic - HMG CoA Reductase Inhibitors (statins)	26.8%	22.2	\$0.10	150.6	\$7.7	63.5%	Y	Y
J35 - CHRONIC DISEASES OF TONSILS AND ADENOIDS	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	26.6%	17.8	\$0.30	207.5	\$17.3	99.9%	Y	N
K01 - EMBEDDED AND IMPACTED TEETH	AMOXICILLIN	Aminopenicillin Antibiotic	26.1%	23.6	\$0.10	223.1	\$5.3	99.8%	Y	N
J21 - ACUTE BRONCHITIS	ALBUTEROL SULFATE	Asthma/COPD Therapy - Beta 2-Adrenergic Agents, Inhaled, Short Acting	24.9%	80.2	\$0.08	63.9	\$15.2	21.3%	Y	Y
O42 - PREMATURE RUPTURE OF MEMBRANES	IBUPROFEN	NSAID Analgesics (COX Non-Specific) - Propionic Acid Derivatives	24.3%	9.9	\$0.09	189.1	\$6.0	67.1%	Y	Y
K02 - DENTAL CARIES	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	24.0%	37.8	\$0.30	207.5	\$17.3	99.9%	Y	N
M32 - SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)	PREDNISON	Glucocorticoids	23.9%	10.7	\$0.04	85.4	\$6.2	48.5%	Y	N
H65 - NONSUPPURATIVE OTITIS MEDIA	AMOXICILLIN	Aminopenicillin Antibiotic	23.3%	69.5	\$0.10	223.1	\$5.3	99.8%	Y	N
J03 - ACUTE TONSILLITIS	AMOXICILLIN	Aminopenicillin Antibiotic	23.2%	37.1	\$0.10	223.1	\$5.3	99.8%	Y	N
N89 - OTHER NONINFLAMMATORY DISORDERS OF VAGINA	FLUCONAZOLE	Antifungal - Triazoles	22.7%	96.5	\$0.04	62.7	\$6.2	98.9%	Y	N
K80 - CHOLELITHIASIS	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	22.5%	32.5	\$0.30	207.5	\$17.3	99.9%	Y	N
E03 - OTHER HYPOTHYROIDISM	LEVOTHYROXINE SODIUM	Thyroid Hormones - Synthetic T4 (Thyroxine)	22.3%	111.3	\$0.15	117.0	\$15.3	95.1%	Y	Y
K01 - EMBEDDED AND IMPACTED TEETH	IBUPROFEN	NSAID Analgesics (COX Non-Specific) - Propionic Acid Derivatives	21.9%	23.6	\$0.09	189.1	\$6.0	67.1%	Y	Y
J20 - ACUTE BRONCHITIS	AZITHROMYCIN	Macrolide Antibiotics	21.8%	137.0	\$0.08	110.7	\$8.4	95.9%	Y	N
J02 - ACUTE PHARYNGITIS	AMOXICILLIN	Aminopenicillin Antibiotic	20.9%	565.7	\$0.10	223.1	\$5.3	99.8%	Y	N
L02 - CUTANEOUS ABSCESS, FURUNCLE AND CARBUNCLE	SULFAMETHOXAZOLE-TRIMETHOPRIM	Antibacterial Folate Antagonist - Other Combinations	20.5%	69.3	\$0.03	46.8	\$7.2	92.0%	Y	N
L01 - IMPETIGO	CEPHALEXIN	Cephalosporin Antibiotics - 1st Generation	20.1%	10.4	\$0.05	46.3	\$12.1	99.6%	Y	N
N76 - OTHER INFLAMMATION OF VAGINA AND VULVA	FLUCONAZOLE	Antifungal - Triazoles	19.8%	59.8	\$0.04	62.7	\$6.2	98.9%	Y	N
B19 - UNSPECIFIED VIRAL HEPATITIS	BUPRENORPHINE-NALOXONE	Agents for Opioid Withdrawal, Opioid-Type	19.5%	23.8	\$2.90	386.9	\$90.0	96.6%	Y	Y
J40 - BRONCHITIS, NOT SPECIFIED AS ACUTE OR CHRONIC	AZITHROMYCIN	Macrolide Antibiotics	18.9%	41.6	\$0.08	110.7	\$8.4	95.9%	Y	N
O21 - EXCESSIVE VOMITING IN PREGNANCY	PROMETHAZINE HCL	Antihistamines - 1st Generation	18.8%	16.9	\$0.02	52.9	\$5.5	54.6%	Y	N
K81 - CHOLECYSTITIS	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	18.7%	9.2	\$0.30	207.5	\$17.3	99.9%	Y	N
L08 - OTHER LOCAL INFECTIONS OF SKIN AND SUBCUTANEOUS TISSUE	MUPIROCI	Dermatological - Antibacterial Other	18.7%	10.1	\$0.04	27.5	\$17.1	100.0%	Y	N
J45 - ASTHMA	VENTOLIN HFA	Asthma/COPD Therapy - Beta 2-Adrenergic Agents, Inhaled, Short Acting	18.6%	225.1	\$1.10	230.5	\$57.4	76.6%	N	Y
M10 - GOUT	ALLOPURINOL	Hyperuricemia Therapy - Xanthine Oxidase Inhibitors	18.5%	9.5	\$0.02	18.9	\$12.3	95.5%	Y	Y
O23 - INFECTIONS OF GENITOURINARY TRACT IN PREGNANCY	NITROFURANTOIN MONO-MACRO	Urinary Antibacterial - Nitrofurantoin Derivatives	18.4%	12.1	\$0.04	21.5	\$22.0	87.5%	Y	N
N20 - CALCULUS OF KIDNEY AND URETER	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	18.4%	54.4	\$0.30	207.5	\$17.3	99.9%	Y	N
Z39 - ENCOUNTER FOR MATERNAL POSTPARTUM CARE AND EXAMINATION	IBUPROFEN	NSAID Analgesics (COX Non-Specific) - Propionic Acid Derivatives	18.3%	52.3	\$0.09	189.1	\$6.0	67.1%	Y	Y
J20 - ACUTE BRONCHITIS	VENTOLIN HFA	Asthma/COPD Therapy - Beta 2-Adrenergic Agents, Inhaled, Short Acting	17.8%	137.0	\$1.10	230.5	\$57.4	76.6%	N	Y
H10 - CONJUNCTIVITIS	POLYMYXIN B SUL-TRIMETHOPRIM	Ophthalmic Antibacterial Mixtures	17.3%	45.2	\$0.01	12.6	\$11.8	97.4%	Y	N
M47 - SPONDYLOSIS	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	17.2%	118.8	\$0.30	207.5	\$17.3	99.9%	Y	N
A08 - VIRAL AND OTHER SPECIFIED INTESTINAL INFECTIONS	ONDANSETRON ODT	Antiemetic - Selective Serotonin 5-HT3 Antagonists	17.1%	37.5	\$0.04	67.2	\$6.3	52.8%	Y	Y
Z94 - TRANSPLANTED ORGAN AND TISSUE STATUS	TACROLIMUS	Immunosuppressive - Calcineurin Inhibitors	17.0%	9.2	\$0.05	2.3	\$247.4	85.4%	Y	N

M32 - SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)	HYDROXYCHLOROQUINE SULFATE	Antimalarials	16.8%	10.7	\$0.06	5.9	\$130.5	96.3%	Y	Y
O13 - GESTATIONAL HYPERTENSION WITHOUT SIGNIFICANT PROTEINURIA	IBUPROFEN	NSAID Analgesics (COX Non-Specific) - Propionic Acid Derivatives	16.6%	11.7	\$0.09	189.1	\$6.0	67.1%	Y	Y
F19 - OTHER PSYCHOACTIVE SUBSTANCE RELATED DISORDERS	BUPRENORPHINE-NALOXONE	Agents for Opioid Withdrawal, Opioid-Type	16.6%	99.8	\$2.90	386.9	\$90.0	96.6%	Y	Y
J00 - ACUTE NASOPHARYNGITIS [COMMON COLD]	BROMPHENIRAMINE-PSEUDOEPHED-DM	Non-Opioid Antitussive-1st Gen. Antihistamine-Decongestant Com	16.4%	35.9	\$0.15	78.1	\$23.3	98.8%	Y	N
M51 - THORACIC, THORACOLUM, AND LUMBOSACRAL INTVRT DISC DISORDERS	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	16.4%	171.8	\$0.30	207.5	\$17.3	99.9%	Y	N
J40 - BRONCHITIS, NOT SPECIFIED AS ACUTE OR CHRONIC	VENTOLIN HFA	Asthma/COPD Therapy - Beta 2-Adrenergic Agents, Inhaled, Short A	16.3%	41.6	\$1.10	230.5	\$57.4	76.6%	N	Y
L20 - ATOPIC DERMATITIS	TRIAMCINOLONE ACETONIDE	Dermatological - Glucocorticoid	16.2%	20.2	\$0.03	36.0	\$11.0	45.1%	Y	N
G89 - PAIN, NOT ELSEWHERE CLASSIFIED	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	16.1%	83.3	\$0.30	207.5	\$17.3	99.9%	Y	N
L25 - UNSPECIFIED CONTACT DERMATITIS	TRIAMCINOLONE ACETONIDE	Dermatological - Glucocorticoid	16.0%	9.7	\$0.03	36.0	\$11.0	45.1%	Y	N
J01 - ACUTE SINUSITIS	AMOXICILLIN-CLAVULANATE POTASS	Aminopenicillin Antibiotic - Beta-lactamase Inhibitor Combinatio	15.9%	185.2	\$0.10	69.6	\$17.5	99.7%	Y	N
O34 - MATERNAL CARE FOR ABNORMALITY OF PELVIC ORGANS	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	15.9%	41.5	\$0.17	64.8	\$32.1	99.0%	Y	N
J20 - ACUTE BRONCHITIS	PREDNISON	Glucocorticoids	15.7%	137.0	\$0.04	85.4	\$6.2	48.5%	Y	N
S39 - OTH & UNSP INJURIES OF ABD, LOW BACK, PELV & EXTRN GENITALS	CYCLOBENZAPRINE HCL	Skeletal Muscle Relaxant - Central Muscle Relaxants	15.4%	27.5	\$0.04	92.1	\$4.9	39.8%	Y	N
K52 - OTHER AND UNSP NONINFECTIVE GASTROENTERITIS AND COLITIS	ONDANSETRON ODT	Antiemetic - Selective Serotonin 5-HT3 Antagonists	15.3%	52.3	\$0.04	67.2	\$6.3	52.8%	Y	N
I25 - CHRONIC ISCHEMIC HEART DISEASE	ATORVASTATIN CALCIUM	Antiatherlipidemic - HMG CoA Reductase Inhibitors (statins)	15.3%	63.3	\$0.10	150.6	\$7.7	63.5%	Y	Y
K59 - OTHER FUNCTIONAL INTESTINAL DISORDERS	POLYETHYLENE GLYCOL 3350	Laxative - Saline and Osmotic	15.2%	76.5	\$0.06	39.3	\$18.5	74.2%	Y	Y
O02 - OTHER ABNORMAL PRODUCTS OF CONCEPTION	IBUPROFEN	NSAID Analgesics (COX Non-Specific) - Propionic Acid Derivatives	15.1%	9.9	\$0.09	189.1	\$6.0	67.1%	Y	Y
N40 - BENIGN PROSTATIC HYPERPLASIA	TAMSULOSIN HCL	Prostatic Hypertrophy Agent - alpha-1-Adrenoceptor Antagonists	15.1%	11.2	\$0.04	24.7	\$17.2	96.6%	Y	Y
L25 - UNSPECIFIED CONTACT DERMATITIS	PREDNISON	Glucocorticoids	15.1%	9.7	\$0.04	85.4	\$6.2	48.5%	Y	N
O34 - MATERNAL CARE FOR ABNORMALITY OF PELVIC ORGANS	IBUPROFEN	NSAID Analgesics (COX Non-Specific) - Propionic Acid Derivatives	15.1%	41.5	\$0.09	189.1	\$6.0	67.1%	Y	Y
I21 - ACUTE MYOCARDIAL INFARCTION	CLOPIDOGREL	Platelet Aggregation Inhibitors - Thienopyridine Agents	15.0%	22.2	\$0.01	24.9	\$6.1	90.1%	Y	Y
L30 - OTHER AND UNSPECIFIED DERMATITIS	TRIAMCINOLONE ACETONIDE	Dermatological - Glucocorticoid	15.0%	26.0	\$0.03	36.0	\$11.0	45.1%	Y	N
I21 - ACUTE MYOCARDIAL INFARCTION	METOPROLOL TARTRATE	Beta Blockers Cardiac Selective	14.8%	22.2	\$0.02	53.9	\$4.1	39.1%	Y	Y
S22 - FRACTURE OF RIB(S), STERNUM AND THORACIC SPINE	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	14.7%	12.9	\$0.30	207.5	\$17.3	99.9%	Y	N
I21 - ACUTE MYOCARDIAL INFARCTION	LISINAPRIL	ACE Inhibitors	14.6%	22.2	\$0.05	170.9	\$3.5	93.1%	Y	Y
G25 - OTHER EXTRAPYRAMIDAL AND MOVEMENT DISORDERS	GABAPENTIN	Anticonvulsant - GABA Analogs	14.6%	9.6	\$0.21	229.4	\$11.1	96.5%	Y	Y
K57 - DIVERTICULAR DISEASE OF INTESTINE	METRONIDAZOLE	Antiprotozoal-Antibacterial 1st Generation 2-methyl-5-nitroimid	14.3%	12.3	\$0.03	35.5	\$9.4	100.0%	Y	N
M48 - OTHER SPONDYLOPATHIES	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	14.2%	31.3	\$0.30	207.5	\$17.3	99.9%	Y	N
K04 - DISEASES OF PULP AND PERIAPICAL TISSUES	CLINDAMYCIN HCL	Lincosamide Antibiotics	14.2%	11.7	\$0.02	23.1	\$9.4	89.8%	Y	N
N13 - OBSTRUCTIVE AND REFLUX UROPATHY	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	14.2%	19.8	\$0.30	207.5	\$17.3	99.9%	Y	N
H60 - OTITIS EXTERNA	CIPRODEX	Otic (Ear) - Anti-infective-Glucocorticoid Combinations	14.0%	15.0	\$0.13	7.1	\$218.5	56.1%	N	N
K40 - INGUINAL HERNIA	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	14.0%	10.9	\$0.30	207.5	\$17.3	99.9%	Y	N
S42 - FRACTURE OF SHOULDER AND UPPER ARM	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	13.9%	28.7	\$0.30	207.5	\$17.3	99.9%	Y	N
J01 - ACUTE SINUSITIS	AMOXICILLIN	Aminopenicillin Antibiotic	13.9%	185.2	\$0.10	223.1	\$5.3	99.8%	Y	N
E84 - CYSTIC FIBROSIS	CREON	Digestive Enzyme Mixtures	13.9%	11.5	\$0.19	2.1	\$1,062.3	90.7%	N	Y
O60 - PRETERM LABOR	IBUPROFEN	NSAID Analgesics (COX Non-Specific) - Propionic Acid Derivatives	13.8%	13.9	\$0.09	189.1	\$6.0	67.1%	Y	Y
O02 - OTHER ABNORMAL PRODUCTS OF CONCEPTION	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	13.7%	9.9	\$0.30	207.5	\$17.3	99.9%	Y	N
K04 - DISEASES OF PULP AND PERIAPICAL TISSUES	IBUPROFEN	NSAID Analgesics (COX Non-Specific) - Propionic Acid Derivatives	13.6%	11.7	\$0.09	189.1	\$6.0	67.1%	Y	Y
R11 - NAUSEA AND VOMITING	ONDANSETRON ODT	Antiemetic - Selective Serotonin 5-HT3 Antagonists	13.3%	142.7	\$0.04	67.2	\$6.3	52.8%	Y	N
S02 - FRACTURE OF SKULL AND FACIAL BONES	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	13.3%	11.0	\$0.30	207.5	\$17.3	99.9%	Y	N
K21 - GASTRO-ESOPHAGEAL REFLUX DISEASE	OMEPRAZOLE	Gastric Acid Secretion Reducing Agents - Proton Pump Inhibitors (	13.3%	78.5	\$0.12	221.9	\$6.5	64.6%	Y	Y
I16 - HYPERTENSIVE CRISIS	CARVEDILOL	Alpha-Beta Blockers	13.2%	9.6	\$0.01	36.9	\$4.6	87.3%	Y	Y
M47 - SPONDYLOSIS	GABAPENTIN	Anticonvulsant - GABA Analogs	13.2%	118.8	\$0.21	229.4	\$11.1	96.5%	Y	Y
L03 - CELLULITIS AND ACUTE LYMPHANGITIS	SULFAMETHOXAZOLE-TRIMETHOPRIM	Antibacterial Folate Antagonist - Other Combinations	13.2%	85.7	\$0.03	46.8	\$7.2	92.0%	Y	Y
I21 - ACUTE MYOCARDIAL INFARCTION	ASPIRIN EC	Platelet Aggregation Inhibitors - Salicylates	13.2%	22.2	\$0.01	61.9	\$2.3	79.4%	Y	N
T84 - COMPLICATIONS OF INTERNAL ORTHOPEDIC PROSTH DEV/GRFT	HYDROCODONE-ACETAMINOPHEN	Analgesic Opioid Hydrocodone and Non-Salicylate Combinations	13.2%	10.9	\$0.30	207.5	\$17.3	99.9%	Y	N
J45 - ASTHMA	MONTELUKAST SODIUM	Asthma Therapy - Leukotriene Receptor Antagonists	13.1%	225.1	\$0.19	187.4	\$12.2	99.9%	Y	Y
K02 - DENTAL CARIES	AMOXICILLIN	Aminopenicillin Antibiotic	13.1%	37.8	\$0.10	223.1	\$5.3	99.8%	Y	N
I16 - HYPERTENSIVE CRISIS	AMLODIPINE BESYLATE	Calcium Channel Blockers - Dihydropyridines	13.0%	9.6	\$0.03	109.3	\$3.4	92.7%	Y	N
N39 - OTHER DISORDERS OF URINARY SYSTEM	NITROFURANTOIN MONO-MACRO	Urinary Antibacterial - Nitrofurane Derivatives	12.9%	176.6	\$0.04	21.5	\$22.0	87.5%	Y	N
L08 - OTHER LOCAL INFECTIONS OF SKIN AND SUBCUTANEOUS TISSUE	SULFAMETHOXAZOLE-TRIMETHOPRIM	Antibacterial Folate Antagonist - Other Combinations	12.9%	10.1	\$0.03	46.8	\$7.2	92.0%	Y	N
M10 - GOUT	PREDNISON	Glucocorticoids	12.8%	9.5	\$0.04	85.4	\$6.2	48.5%	Y	N

1. Calculated as % of days supply prescribed since first diagnosis in the reporting period


Reporting Period: October  
2018 to December 2018

Specialty drugs are generally high-cost medications used to treat highly complex or rare chronic conditions. More and more specialty drugs are coming into the market each year, and are contributing to a higher percentage of overall pharmacy cost. This section shows key metrics for the specialty drugs identified by Evolent Pharmacy Team.

KPI by Generic and Specialty Status								
Metric	Generic Non-Specialty		Brand Non-Specialty		Generic Specialty		Brand Specialty	
	Value	Performance Indicator <sup>1</sup>	Value	Performance Indicator <sup>1</sup>	Value	Performance Indicator <sup>1</sup>	Value	Performance Indicator <sup>1</sup>
Paid PMPM	\$18.19	↑	\$25.90	↓	\$0.81	↑	\$20.35	↑
Member Responsibility PMPM	\$0.15	↑	\$0.05	↓	\$0.00	↑	\$0.00	↑
Ingredient Cost PMPM	\$16.39	↑	\$25.92	↓	\$0.81	↑	\$20.47	↑
% of Members with ≥ 1 Rx Claim	31.3%	↑	13.1%	↑	0.1%	↑	0.5%	↑
Scripts per 1,000	9,145.6	↑	1,414.1	↑	10.9	↓	51.3	↑
Overall Paid per Script	\$23.9	↑	\$219.8	↓	\$895.4	↑	\$4,761.7	↓

1. Based on current to prior reporting period % change - change within ± 2% indicated by ●.

The rolling 12-months graph below shows a steady increase in the utilization of specialty drugs for this population.



The table below displays the top 25 specialty drugs contributing to 21.99% of total pharmacy spend in the reporting period. The prescriptions are also grouped by prescriber specialty and individual providers with the highest contribution to total spend.

Top 25 Specialty Drugs by Total Paid									
Drug	Drug Class (GPI 4)	Scripts/1,000	Member Responsibility/Script	Member Responsibility%	Paid/Script	Total Paid	% of Specialty Drug Spend	% of Total Rx Spend	
MAVYRET	HEPATITIS AGENTS	3.59	\$0.58	0.00%	\$13,312.4	\$3,780,729	18.84%	6.04%	
HUMIRA PEN	ANTI-TNF-ALPHA - MONOCLONAL ANTIBODIES	3.42	\$1.04	0.02%	\$6,076.8	\$1,640,723	8.18%	2.62%	
NORDITROPIN FLEXPRO	GROWTH HORMONES	2.64	\$0.06	0.00%	\$5,069.5	\$1,059,528	5.28%	1.69%	
SYNAGIS	MONOCLONAL ANTIBODIES	3.19	\$0.00	0.00%	\$2,561.8	\$645,577	3.22%	1.03%	
VIVITROL	OPIOID ANTAGONISTS	5.66	\$0.26	0.02%	\$1,320.0	\$590,028	2.94%	0.94%	
EPCLUSA	HEPATITIS AGENTS	0.29	\$0.00	0.00%	\$24,140.2	\$555,224	2.77%	0.89%	
STELARA	ANTIPSORIATICS	0.40	\$0.75	0.00%	\$17,207.5	\$550,641	2.74%	0.88%	
GENVOYA	ANTIRETROVIRALS	2.08	\$0.07	0.00%	\$2,963.3	\$485,979	2.42%	0.78%	
TRIUVEQ	ANTIRETROVIRALS	2.13	\$0.05	0.00%	\$2,790.3	\$468,765	2.34%	0.75%	
ENBREL SURECLICK	SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR AGENTS	1.10	\$0.69	0.01%	\$5,175.9	\$450,307	2.24%	0.72%	
SYMDEKO	CYSTIC FIBROSIS AGENTS	0.19	\$0.00	0.00%	\$22,514.7	\$337,721	1.68%	0.54%	
DESCOXY	ANTIRETROVIRALS	2.47	\$0.02	0.00%	\$1,668.9	\$325,431	1.62%	0.52%	
KALYDECO	CYSTIC FIBROSIS AGENTS	0.16	\$0.00	0.00%	\$24,018.5	\$312,240	1.56%	0.50%	
BIKTARVY	ANTIRETROVIRALS	1.32	\$0.23	0.01%	\$2,963.1	\$308,163	1.54%	0.49%	
TIVICAY	ANTIRETROVIRALS	2.19	\$0.02	0.00%	\$1,644.3	\$284,469	1.42%	0.45%	
TECFIDERA	MULTIPLE SCLEROSIS AGENTS	0.49	\$0.31	0.00%	\$7,238.6	\$282,305	1.41%	0.45%	
FABRAZYME	METABOLIC MODIFIERS	0.19	\$0.00	0.00%	\$18,448.3	\$276,724	1.38%	0.44%	
VIGABATRIN	GABA MODULATORS	0.18	\$0.00	0.00%	\$17,247.6	\$241,467	1.20%	0.39%	
TRUVADA	ANTIRETROVIRALS	1.49	\$1.39	0.08%	\$1,679.4	\$198,175	0.99%	0.32%	
ENBREL	SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR AGENTS	0.48	\$1.16	0.02%	\$4,718.7	\$179,309	0.89%	0.29%	
AUBAGIO	MULTIPLE SCLEROSIS AGENTS	0.33	\$0.77	0.01%	\$6,632.4	\$172,443	0.86%	0.28%	
PULMOZYME	CYSTIC FIBROSIS AGENTS	0.56	\$0.00	0.00%	\$3,775.4	\$166,118	0.83%	0.27%	
XOLAIR	ANTI-ASTHMATIC - MONOCLONAL ANTIBODIES	0.77	\$0.72	0.03%	\$2,601.7	\$158,706	0.79%	0.25%	
IMBRUVICA	ANTINEOPLASTIC ENZYME INHIBITORS	0.16	\$0.00	0.00%	\$11,678.7	\$151,823	0.76%	0.24%	
DUPIXENT	ECZEMA AGENTS	0.65	\$0.78	0.03%	\$2,976.5	\$151,802	0.76%	0.24%	

**Top 10 Specialties (Non-PCP) by Total Specialty Drug Paid**

Specialty	Total Scripts	Total Paid	Paid/ Script	Unique Specialty Drugs	Unique Members	Scripts/1000	Scripts/ Encounter (E&M)	Most Prescribed Drug (by Total Paid)	
								Name	% of Total Paid
Neurology	149	\$1,151,949	\$7,731.2	20	59	1.9	1.2	TECFIDERA	20.6%
Rheumatology	257	\$1,048,835	\$4,081.1	23	95	3.3	1.0	HUMIRA PEN	27.5%
Dermatology	165	\$964,991	\$5,848.4	12	81	2.1	1.1	HUMIRA PEN	49.2%
Physician Assistant	322	\$937,223	\$2,910.6	42	113	4.1	1.1	MAVYRET	15.6%
Pulmonary Disease	64	\$753,968	\$11,780.7	7	19	0.8	1.1	SYMDEKO	38.8%
Endocrinology	103	\$488,285	\$4,740.6	4	41	1.3	1.0	NORDITROPIN FLEXPEN	96.2%
Allergy/Immunology	53	\$170,199	\$3,211.3	4	20	0.7	1.0	XOLAIR	55.4%
General Surgery	87	\$155,363	\$1,785.8	12	22	1.1	1.0	NEXAVAR	72.7%
Gastroenterology	44	\$134,754	\$3,062.6	6	14	0.6	1.0	STELARA	77.0%
Psychiatry	54	\$103,422	\$1,915.2	5	26	0.7	1.2	VIVITROL	48.6%

**Top 25 Providers by Total Specialty Drug Paid**



Provider	Specialty	Total Scripts	Total Paid	Paid/Script	Unique Specialty Drugs	Unique Members
CECIL, BENNET	Internal Medicine	82	\$691,232	\$8,429.7	5	46
SMART, LAURA	Internal Medicine	53	\$681,358	\$12,855.8	9	28
JOHNSON, TRACY	Nurse Practitioner	214	\$402,921	\$1,882.8	17	51
BRIGGS, WILLIAM	Physician Assistant	215	\$401,653	\$1,868.2	21	65
CAVE, BARBRA	Nurse Practitioner	26	\$390,477	\$15,018.4	3	14
WOODRUFF, KELLIE	Nurse Practitioner	71	\$366,448	\$5,161.2	2	21
REVERT, DANIELLE	Nurse Practitioner	31	\$333,580	\$10,760.7	5	24
BICKEL, SCOTT	Pulmonary Disease	21	\$326,912	\$15,567.2	7	8
DEDINA, DIONYZIA	Nurse Practitioner	144	\$325,786	\$2,262.4	17	45
MORTON, RONALD	Pulmonary Disease	27	\$295,851	\$10,957.4	4	9
FOSTER, MICHAEL	Endocrinology	36	\$242,287	\$6,730.2	2	16
ASAMOAH, ALEXANDER	Pediatric Medicine	25	\$233,495	\$9,339.8	3	7
RAGHURAM, ANUPAMA	Internal Medicine	89	\$213,294	\$2,396.6	14	25
STEWART, NATOYA	Nurse Practitioner	15	\$209,118	\$13,941.2	3	9
GLISSON, SHAWN	Internal Medicine	8	\$200,157	\$25,019.6	3	3
SAJID, SALEEM	Rheumatology	42	\$192,572	\$4,585.0	8	17
REEVES, JEFFERY	Internal Medicine	23	\$190,863	\$8,298.4	4	15
GANESH, GEETA	Neurology	26	\$181,049	\$6,963.4	5	11
LAKHOTIA, ARPITA	Neurology	11	\$177,232	\$16,112.0	3	2
TUCKER, CLINT	Dermatology	32	\$168,018	\$5,250.6	9	17
SCHULZ, PAUL	Internal Medicine	47	\$158,897	\$3,380.8	6	18
EL-KERSCH, KARIM	Internal Medicine	11	\$158,057	\$14,368.8	3	3
WILLIAMS, PATRICK	Internal Medicine	14	\$155,216	\$11,086.9	4	4
FOSTER, MARY	Nurse Practitioner	3	\$142,596	\$47,531.9	1	1
VORA, RAJU	Internal Medicine	9	\$139,837	\$15,537.4	4	3

**Supply Chain**  
Pharmacy Analytics Report

Reporting Period: October 2018 to  
December 2018

This section of the report investigates specialty medication billed under the medical benefits, and dives into the difference in cost based on the site of administration (inpatient versus outpatient, for example). The data below shows there are opportunities within this population if certain medications are administered in a different setting.

**By Site of Care**



**Top 10 by Site of Service**


Drug	IP			OP			Physician Office			Home Health		
	Unit Cost	Volume	Total Cost	Unit Cost	Volume	Total Cost	Unit Cost	Volume	Total Cost	Unit Cost	Volume	Total Cost
GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSF)	\$0.7	9,000	\$6,053	\$73.8	7,136	\$526,860	-	0	\$0	\$1.0	38,800	\$38,293
N/A	\$6.0	423	\$2,533	\$2.3	23,971	\$55,798	-	0	\$0	\$99.5	203	\$20,202
RANK LIGAND (RANKL) INHIBITORS	\$369.3	3	\$1,108	\$12.8	6,006	\$76,965	-	0	\$0	-	-	\$0
LOW MOLECULAR WEIGHT HEPARINS	\$1.8	354	\$633	\$2.0	4,209	\$8,221	-	0	\$0	\$8.2	1,544	\$12,671
IMMUNE SERUMS	\$285.1	1	\$285	\$39.6	5,607	\$222,181	-	0	\$0	\$57.4	16,080	\$923,771
BISPHOSPHONATES	\$23.4	5	\$117	\$32.4	165	\$5,340	-	0	\$0	-	-	\$0
ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)	\$0.8	32	\$25	\$8.6	2,137	\$18,354	-	0	\$0	-	-	\$0
ALKYLATING AGENTS	-	-	\$0	\$1.9	29,390	\$56,213	-	0	\$0	-	-	\$0
ALPHA-PROTEINASE INHIBITOR (HUMAN)	-	-	\$0	\$0.7	499	\$360	-	0	\$0	\$1.7	38,058	\$64,537
ANTI-IGE MONOCLONAL ANTIBODIES	-	-	\$0	\$29.3	1,560	\$45,712	-	0	\$0	-	-	\$0

**Top 25 Drugs by % of Total PMPM**

GPI6	% of Total PMPM	IP		OP		Physician Office		Home Health	
		Unit Cost	# of Scripts	Unit Cost	# of Scripts	Unit Cost	# of Scripts	Unit Cost	# of Scripts
ANTINEOPLASTIC - MONOCLONAL ANTIBODIES	24.4%	\$0.0	7	\$39.6	69,889	-	0	-	0
ANTIHEMOPHILIC PRODUCTS	13.2%	-	0	\$0.0	11,470	-	0	\$92.4	17,376
IMMUNE SERUMS	9.7%	\$285.1	1	\$39.6	5,607	-	0	\$57.4	16,080
GRANULOCYTE COLONY-STIMULATING FACTORS (G-CSF)	4.9%	\$0.7	9,000	\$73.8	7,136	-	0	\$1.0	38,800
MULTIPLE SCLEROSIS AGENTS - MONOCLONAL ANTIBODIES	4.8%	-	0	\$37.5	15,310	-	0	\$18.7	300
TUMOR NECROSIS FACTOR ALPHA BLOCKERS	4.8%	-	0	\$82.5	5,058	-	0	\$107.3	510
ANTIHEMOPHILIC PRODUCTS - MONOCLONAL ANTIBODIES	3.9%	-	0	-	0	-	0	\$48.3	9,690
COMPLEMENT INHIBITORS	3.7%	-	0	\$197.4	2,250	-	0	-	0
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITORS	3.6%	-	0	\$68.9	6,183	-	0	-	0
MUSCULAR DYSTROPHY AGENTS	2.6%	-	0	-	0	-	0	\$222.2	1,400
INTEGRIN RECEPTOR ANTAGONISTS	2.4%	-	0	\$16.0	10,200	-	0	\$20.3	4,500
PROGESTIN CONTRACEPTIVES - IMPLANTS	2.1%	-	0	\$1,074.7	34	-	0	-	0
ANTIMETABOLITES	1.9%	\$0.0	3	\$18.1	10,915	-	0	\$7.0	78
MITOTIC INHIBITORS	1.5%	-	0	\$4.3	42,308	-	0	-	0
PROGESTIN CONTRACEPTIVES - IUD	1.3%	-	0	\$744.4	21	-	0	-	0
N/A	1.0%	\$6.0	423	\$2.3	23,971	-	0	\$99.5	203
ANTINEOPLASTIC ENZYMES	1.0%	-	0	\$13,359.2	9	-	0	-	0
ANTINEOPLASTIC - PROTEASOME INHIBITORS	0.9%	-	0	\$38.6	2,758	-	0	-	0
ANTINEOPLASTIC ANTIBODY-DRUG COMPLEXES	0.8%	-	0	\$76.2	1,320	-	0	-	0
LHRH/GNRH AGONIST ANALOG PITUITARY SUPPRESSANTS	0.8%	-	0	\$1,285.9	18	-	0	\$751.1	4
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ANTAGONISTS	0.7%	-	0	-	0	-	0	-	0
RANK LIGAND (RANKL) INHIBITORS	0.7%	\$369.3	3	\$12.8	6,006	-	0	-	0
FABRY DISEASE - AGENTS	0.7%	-	0	\$0.0	149	-	0	\$561.1	150
NEUROMUSCULAR BLOCKING AGENT - NEUROTOXINS	0.7%	-	0	\$0.9	31,417	-	0	-	0
ALPHA-PROTEINASE INHIBITOR (HUMAN)	0.5%	-	0	\$0.7	499	-	0	\$1.7	38,058

Compared to retail pharmacies, mail order prescriptions are more likely to provide a larger supply (90-days instead of 30-days) and a lower unit cost for the same medication. Below are the top maintenance drugs with potential saving opportunities if they are filled by mail order instead of retail.

**Cost & Use by Distribution Channel**



**Top 25 Maintenance Drugs by Savings Opportunity**

Drug Name	Scripts/K	PMPM	Total Paid	% Filled		% 90-day Supply		Unit Cost		Savings Opportunity	
				mail order	by Retail	mail order	by Retail	mail order	by Retail	Total \$	%
HUMAN INSULIN	118.0	\$5.04	\$4,783,792	0.0%	98.5%	0.0%	0.0%	\$16.1	\$19.2	\$777,849	16.3%
BENZISOXAZOLES	45.8	\$0.99	\$938,797	0.1%	83.3%	0.0%	0.1%	\$1.2	\$4.8	\$319,357	34.0%
ADRENERGIC COMBINATIONS	126.6	\$3.45	\$3,268,512	0.0%	98.6%	0.0%	0.0%	\$10.6	\$11.2	\$187,974	5.8%
CENTRAL MUSCLE RELAXANTS	103.3	\$0.21	\$195,173	0.0%	98.9%	0.0%	0.0%	\$0.2	\$0.9	\$141,933	72.7%
NONSTEROIDAL ANTI-INFLAMMATORY AGENTS (NSAIDS)	360.5	\$0.21	\$197,121	0.0%	97.9%	0.0%	1.5%	\$0.1	\$0.3	\$116,168	58.9%
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS)	416.0	\$0.20	\$187,252	0.0%	96.4%	0.0%	0.0%	\$0.1	\$0.2	\$90,080	48.1%
PROTON PUMP INHIBITORS	343.2	\$0.23	\$222,078	0.0%	98.4%	0.0%	0.0%	\$0.2	\$0.3	\$79,525	35.8%
COMBINATION CONTRACEPTIVES - ORAL	87.9	\$0.15	\$145,338	0.0%	99.4%	0.0%	0.0%	\$0.3	\$0.6	\$77,902	53.6%
DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS	28.5	\$1.01	\$962,057	0.1%	98.1%	0.0%	0.0%	\$13.3	\$14.3	\$68,001	7.1%
ANTIDEPRESSANTS - MISC.	92.9	\$0.16	\$147,490	0.0%	96.2%	0.0%	0.0%	\$0.4	\$0.7	\$63,228	42.9%
LEUKOTRIENE RECEPTOR ANTAGONISTS	187.6	\$0.19	\$183,386	0.0%	98.9%	0.0%	0.0%	\$0.3	\$0.4	\$62,402	34.0%
SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS	22.0	\$0.84	\$800,196	0.2%	99.3%	0.0%	0.0%	\$14.2	\$15.4	\$60,174	7.5%
ANTIAXIETY AGENTS - MISC.	78.9	\$0.10	\$91,522	0.0%	94.7%	0.0%	0.0%	\$0.2	\$0.5	\$50,162	54.8%
BIGUANIDES	118.3	\$0.06	\$60,729	0.1%	97.9%	100.0%	15.1%	\$0.1	\$0.2	\$40,009	65.9%
LOOP DIURETICS	62.9	\$0.05	\$46,556	0.0%	97.3%	100.0%	8.1%	\$0.0	\$0.3	\$38,563	82.8%
BETA BLOCKERS CARDIO-SELECTIVE	138.2	\$0.12	\$117,961	0.0%	98.6%	100.0%	14.9%	\$0.2	\$0.3	\$37,567	31.8%
FIBRIC ACID DERIVATIVES	32.2	\$0.11	\$100,956	0.2%	98.0%	0.0%	0.0%	\$0.8	\$1.3	\$36,049	35.7%
CALCIUM CHANNEL BLOCKERS	136.2	\$0.09	\$82,174	0.0%	98.4%	0.0%	13.4%	\$0.1	\$0.2	\$33,392	40.6%
ANGIOTENSIN II RECEPTOR ANTAGONISTS	58.2	\$0.04	\$41,350	0.0%	98.6%	100.0%	14.2%	\$0.1	\$0.2	\$30,377	73.5%
THYROID HORMONES	128.4	\$0.18	\$172,529	0.0%	98.1%	0.0%	13.1%	\$0.4	\$0.5	\$28,038	16.3%
GOUT AGENTS	21.5	\$0.07	\$63,117	0.1%	98.2%	0.0%	0.0%	\$0.7	\$1.3	\$25,867	41.0%
THIAZIDES AND THIAZIDE-LIKE DIURETICS	89.7	\$0.06	\$54,879	0.0%	98.7%	50.0%	8.4%	\$0.1	\$0.2	\$25,469	46.4%
POTASSIUM	51.5	\$0.08	\$75,346	0.0%	96.9%	0.0%	0.0%	\$0.4	\$0.6	\$24,025	31.9%
THIENOPYRIDINE DERIVATIVES	27.6	\$0.04	\$34,001	0.0%	97.3%	100.0%	14.6%	\$0.1	\$0.4	\$23,635	69.5%
GLUCOSE MONITORING TEST SUPPLIES	32.7	\$0.05	\$44,811	0.0%	98.8%	0.0%	0.3%	\$0.3	\$0.6	\$21,007	46.9%